Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Valis

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2021
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a TrialJean-Christophe Corvol, Jean-Philippe Azulay, Björn Bosse, et al.
Molecules (Basel, Switzerland)|November 15, 2018
Molecular Modeling and In Vitro Studies of a Neutral Oxime as a Potential Reactivator for Acetylcholinesterase Inhibited by ParaoxonReuel L de Paula, Joyce S F D de Almeida, Samir F A Cavalcante, et al.
BMC Pharmacology & Toxicology|February 23, 2018
A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesteraseKamil Kuca, Kamil Musilek, Daniel Jun, et al.
Journal of Biomolecular Structure & Dynamics|February 23, 2023
Anastrozole-mediated modulation of mitochondrial activity by inhibition of mitochondrial permeability transition pore opening: an initial perspectiveSomesh Kumar, Neha Choudhary, Mohammed Faruq, et al.
Multiple Sclerosis and Related Disorders|June 22, 2023
Is breastfeeding in MS harmful or not? An answer from real-world Czech dataPavel Hradilek, Olga Zapletalova, Petra Hanulikova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Bioorganic Chemistry|January 9, 2021
Tacrine - Benzothiazoles: Novel class of potential multitarget anti-Alzheimeŕs drugs dealing with cholinergic, amyloid and mitochondrial systemsEugenie Nepovimova, Lucie Svobodova, Rafael Dolezal, et al.
European Journal of Medicinal Chemistry|March 10, 2019
Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's diseaseKatarina Chalupova, Jan Korabecny, Manuela Bartolini, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Movement Disorders : Official Journal of the Movement Disorder Society|October 28, 2021
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a TrialJean-Christophe Corvol, Jean-Philippe Azulay, Björn Bosse, et al.
Molecules (Basel, Switzerland)|November 15, 2018
Molecular Modeling and In Vitro Studies of a Neutral Oxime as a Potential Reactivator for Acetylcholinesterase Inhibited by ParaoxonReuel L de Paula, Joyce S F D de Almeida, Samir F A Cavalcante, et al.
BMC Pharmacology & Toxicology|February 23, 2018
A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesteraseKamil Kuca, Kamil Musilek, Daniel Jun, et al.
Journal of Biomolecular Structure & Dynamics|February 23, 2023
Anastrozole-mediated modulation of mitochondrial activity by inhibition of mitochondrial permeability transition pore opening: an initial perspectiveSomesh Kumar, Neha Choudhary, Mohammed Faruq, et al.
Multiple Sclerosis and Related Disorders|June 22, 2023
Is breastfeeding in MS harmful or not? An answer from real-world Czech dataPavel Hradilek, Olga Zapletalova, Petra Hanulikova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trialPeter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, et al.
Bioorganic Chemistry|January 9, 2021
Tacrine - Benzothiazoles: Novel class of potential multitarget anti-Alzheimeŕs drugs dealing with cholinergic, amyloid and mitochondrial systemsEugenie Nepovimova, Lucie Svobodova, Rafael Dolezal, et al.
European Journal of Medicinal Chemistry|March 10, 2019
Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's diseaseKatarina Chalupova, Jan Korabecny, Manuela Bartolini, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 4, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 studyAmit Bar-Or, Heinz Wiendl, Xavier Montalban, et al.
Pageof 11